Join
Live feed
·
PRReleasevia Quantisnow
eFFECTOR Therapeutics Inc. logo

eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
EFTR· eFFECTOR Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EFTR (eFFECTOR Therapeutics Inc.) and more on Quantisnow.